XBIT · Insider Trading
XBiotech Inc
Every open-market purchase and sale reported by XBIT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-28 | John Simard | Director | Buy | +368,524 | +$711.25K |
| 2026-10-28 | Jan-Paul Simard | Co-Chief Executive Officer | A | +2,000,000 deriv. | — |
| 2025-11-12 | Tevi David Troy | Director | A | +56,000 deriv. | — |
| 2025-11-12 | Thomas Martin Kuendig | Director | A | +79,115 deriv. | — |
| 2025-11-12 | David Spencer Soffer | Director | A | +51,000 deriv. | — |
| 2025-11-12 | Craig Evan Rademaker | Director | A | +92,104 deriv. | — |
| 2025-03-19 | John Simard | Chief Executive Officer | A | +1,026,228 deriv. | — |
| 2025-02-04 | John Simard | Chief Executive Officer | J | −2,470,355 deriv. | — |
| 2024-06-21 | Donald H. MacAdam | Director | A | +37,500 deriv. | — |
| 2024-06-21 | Peter Libby | Director | A | +37,500 deriv. | — |
| 2024-06-21 | Jan-Paul Waldin | Director | A | +37,500 deriv. | — |
| 2024-06-21 | W Thorpe McKenzie | Director | A | +37,500 deriv. | — |
| 2024-01-05 | John Simard | Chief Executive Officer | Buy | +2,470,355 deriv. | — |
| 2023-06-26 | Jan-Paul Waldin | Director | A | +25,000 deriv. | — |
| 2023-06-26 | Donald H. MacAdam | Director | A | +25,000 deriv. | — |
| 2023-06-26 | W Thorpe McKenzie | Director | A | +25,000 deriv. | — |
| 2023-06-26 | Peter Libby | Director | A | +25,000 deriv. | — |
| 2023-02-17 | Sushma Shivaswamy | Chief Scientific Officer | A | +100,000 deriv. | — |
| 2022-06-27 | Donald H. MacAdam | Director | A | +25,000 deriv. | — |
| 2022-06-27 | W Thorpe McKenzie | Director | A | +25,000 deriv. | — |
| 2022-06-27 | Jan-Paul Waldin | Director | A | +25,000 deriv. | — |
| 2022-06-27 | Peter Libby | Director | A | +25,000 deriv. | — |
| 2022-02-15 | John Simard | Chief Executive Officer | Sell | −50,000 | −$657.72K |
| 2022-01-13 | W Thorpe McKenzie | Director | MIXED | +36,507 | −$3 |
| 2021-11-23 | Sushma Shivaswamy | Chief Scientific Officer | A | +100,000 deriv. | — |
| 2021-11-23 | Queena Han | VP Finance & HR | A | +35,000 deriv. | — |
| 2021-10-15 | John Simard | Chief Executive Officer | Sell | −89,286 | −$1.13M |
| 2021-10-06 | John Simard | Chief Executive Officer | Sell | −48,613 | −$624.18K |
| 2021-10-01 | John Simard | Chief Executive Officer | Sell | −60,901 | −$812.12K |
| 2021-09-28 | John Simard | Chief Executive Officer | Sell | −51,200 | −$753.42K |
| 2021-09-22 | John Simard | Chief Executive Officer | Sell | −50,000 | −$757.58K |
| 2021-07-19 | John Simard | Chief Executive Officer | Sell | −50,000 | −$907.35K |
| 2021-07-12 | Donald H. MacAdam | Director | M | +10,000 | +$44.00K |
| 2021-07-12 | Peter Libby | Director | M | +25,000 | +$194.00K |
| 2021-06-24 | Peter Libby | Director | A | +25,000 deriv. | — |
| 2021-06-24 | Donald H. MacAdam | Director | A | +25,000 deriv. | — |
| 2021-06-24 | Jan-Paul Waldin | Director | A | +25,000 deriv. | — |
| 2021-06-24 | W Thorpe McKenzie | Director | A | +25,000 deriv. | — |
| 2021-04-27 | Peter Libby | Director | A | +25,000 deriv. | — |
| 2021-04-27 | John Simard | Chief Executive Officer | A | — | — |
| 2021-03-22 | John Simard | Chief Executive Officer | M | +500,000 | +$3.75M |
| 2021-02-01 | John Simard | Chief Executive Officer | W | −754,619 deriv. | — |
| 2020-12-18 | BAY STREET FINANCIAL S.A. | 10%+ Owner | Sell | −1,173,033 | −$22.03M |
| 2020-12-02 | BAY STREET FINANCIAL S.A. | 10%+ Owner | Sell | −182,836 | −$3.37M |
| 2020-11-20 | W Thorpe McKenzie | Director | Sell | −375,000 | −$6.86M |
| 2020-09-21 | John Simard | Chief Executive Officer | J | −500,000 | — |
| 2020-09-16 | Sushma Shivaswamy | Chief Scientific Officer | MIXED | — | −$500.19K |
| 2020-09-02 | Queena Han | VP Finance & HR | M | +57,692 | +$242.40K |
| 2020-09-01 | Donald H. MacAdam | Director | A | +25,000 deriv. | — |
| 2020-09-01 | W Thorpe McKenzie | Director | A | +25,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| John Simard | Chief Executive Officer | 4,191,690 | $7.84M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the XBIT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.